Skip to content

A randomized controlled trial for clopidogrel at different loading doses in one-stop hybrid coronary revascularization

A randomized controlled trial for clopidogrel at different loading doses in one-stop hybrid coronary revascularization

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018189
Enrollment
Unknown
Registered
2018-09-04
Start date
2018-09-01
Completion date
Unknown
Last updated
2018-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

A:clopidogrel 300mg
B:clopidogrel 450mg
C:clopidogrel 600mg

Sponsors

Beijing Chaoyang Hospital affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Unfavorable LAD for PCI (i.e., chronic total occlusion, excessive tortuosity, severely diffuse lesion),unprotected left main coronary artery disease. Non-LAD lesions were technically feasible for PCI with drug eluting stent (DES). Limitations to traditional CABG, such as pre-existing organs dysfunction, heavily calcified proximal aorta or lack of suitable graft conduits.

Exclusion criteria

Exclusion criteria: Left subclavian artery and LIMA stenosis,buried intramyocardial LAD, need for a concomitant operation,overt congestive heart failure, hemodynamic instability, other conditions rendering PCI unsuitable (e.g., fresh thrombus, coronary vessel diameter < 1.5 mm).

Design outcomes

Primary

MeasureTime frame
during follow-up was the incidence of major adverse cardiac or cerebrovascular events (MACCE);

Secondary

MeasureTime frame
Patency of LIMA-LAD graft and stent;

Countries

China

Contacts

Public ContactPixiong Su

Beijing Chaoyang Hospital affiliated to Capital Medical University

supixiong1130@163.com+86 13910719885

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026